Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): mRNA-1273

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 01, 2020

            Details:

            Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RG6217

            Therapeutic Area: Infections and Infectious Diseases Product Name: RG6217

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 23, 2020

            Details:

            Roche has canned a phase 1 test of a potential hepatitis B antiviral as part of its third-quarter clean-up of unwanted pipeline drugs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): V-306

            Therapeutic Area: Infections and Infectious Diseases Product Name: V-306

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 16, 2020

            Details:

            The financing will ensure the company can complete the phase 1 clinical trial of its lead asset V-306 in RSV, advance pre-clinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LXE408

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 25, 2020

            Details:

            Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials and DNDi will lead Phase II and Phase III development in India.